請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56357完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳沛隆(Pei-Lung Chen) | |
| dc.contributor.author | Tsai-Tzu Wu | en |
| dc.contributor.author | 吳采姿 | zh_TW |
| dc.date.accessioned | 2021-06-16T05:24:55Z | - |
| dc.date.available | 2015-10-09 | |
| dc.date.copyright | 2014-10-09 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-08-14 | |
| dc.identifier.citation | 1. Gómez, M.R., Tuberous Sclerosis Complex. 1999, Cary, NC, USA: Oxford University Press, USA.
2. Green, A.J., M. Smith, and J.R. Yates, Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet, 1994. 6(2): p. 193-6. 3. Gómez, M.R., Phenotypes of the tuberous sclerosis complex with a revision of diagnostic criteria. Ann N Y Acad Sci, 1991. 615: p. 1-7. 4. Sampson, J.R., et al., Genetic aspects of tuberous sclerosis in the west of Scotland. J Med Genet, 1989. 26(1): p. 28-31. 5. O'Callaghan, F.J., et al., Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet, 1998. 351(9114): p. 1490. 6. Northrup, H. and D.A. Krueger, Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol, 2013. 49(4): p. 243-54. 7. Rayer, P.F.O., Traits’ theoriqué et pratique des maladies de la peau. Vol. 3. 1835, Paris, J.B. Baillière. 8. Recklinghausen, F.D.v., Ein Herz von einem Neugeborene welches mehrere theils nach aussen, theils nach den Höhlen prominirende Tumoren (Myomen) trug. Monatschr Geburtsheilkd, 1863. 20: p. 1–2. 9. Bourneville, D.M., Sclérose tubéreuse des circonvolution cérébrales: Idiotie et épilepsie hemiplégique., in Archives de neurologie. 1880, Paris. p. 81-91. 10. Pellizzi, G.B., Contributo allo studio de1 idiozia. Riv. Sperim Freniat, 1901. 27: p. 265-269. 11. Perusini, G., Ueber einen Fall von Sclerosis tuberosa hypertrophica. (Istioatipia corticale disseminata von Pellizzi.). Monatsschr Psychiatr Neurol, 1905. 17: p. 169-192. 12. Vogt, H., Zur Pathologie und pathologischen Anatomie der verschiedenen Idiotieformen. Mschr Psychiat Neurol 1908. 24: p. 106-117. 13. Hoeve, J.v.d., Eye symptoms in tuberous sclerosis of the brain. . Trans Ophthalmol Soc U K 1920. 40: p. 329-334. 14. Dickerson, W.W., CHaracteristic roentgenographic changes associated with tuberous sclerosis. Archives of Neurology & Psychiatry, 1945. 53(3): p. 199-204. 15. Critchley, M. and C. J.C.Earl, Tuberose sclerosis and allied conditions. Brain, 1932. 55(3): p. 311-346. 16. Moolten, S.E., Hamartial nature of the tuberous sclerosis complex and its bearing on the tumor problem: Report of a case with tumor anomaly of the kidney and adenoma sebaceum. Archives of Internal Medicine, 1942. 69(4): p. 589-623. 17. Lagos, J.C. and M.R. Gomez, Tuberous sclerosis: reappraisal of a clinical entity. Mayo Clin Proc, 1967. 42(1): p. 26-49. 18. Donegani, G., F. Gratarolla, and E. Wildi, Tuberous sclerosis. Handb Clin Neurol. Vol. 14. 1972: Amsterdam : North-Holland Pub. Co. 340-389. 19. Gómez, M.R., Tuberous Sclerosis. 1st ed. 1979, New York: Raven Press. 20. Fryer, A.E., et al., Evidence that the gene for tuberous sclerosis is on chromosome 9. Lancet, 1987. 1(8534): p. 659-61. 21. Kandt, R.S., et al., Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat Genet, 1992. 2(1): p. 37-41. 22. Roach, E.S., et al., Diagnostic criteria: tuberous sclerosis complex. Report of the Diagnostic Criteria Committee of the National Tuberous Sclerosis Association. J Child Neurol, 1992. 7(2): p. 221-4. 23. Roach, E.S., M.R. Gomez, and H. Northrup, Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol, 1998. 13(12): p. 624-8. 24. Kenerson, H.L., et al., Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res, 2002. 62(20): p. 5645-50. 25. Franz, D.N., et al., Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol, 2006. 59(3): p. 490-8. 26. Wienecke, R., et al., Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis, 2006. 48(3): p. e27-9. 27. Martin, N., et al., Discordant clinical manifestations in monozygotic twins with the identical mutation in the TSC2 gene. Clin Genet, 2003. 63(5): p. 427-30. 28. Humphrey, A., et al., Monozygotic twins with tuberous sclerosis discordant for the severity of developmental deficits. Neurology, 2004. 62(5): p. 795-8. 29. Napolioni, V., R. Moavero, and P. Curatolo, Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain Dev, 2009. 31(2): p. 104-13. 30. Haemel, A.K., A.L. O'Brian, and J.M. Teng, Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol, 2010. 146(7): p. 715-8. 31. Gutte, R. and U. Khopkar, Unilateral multiple facial angiofibromas: a case report with brief review of literature. Indian J Dermatol, 2013. 58(2): p. 159. 32. Jozwiak, S., et al., Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol, 1998. 37(12): p. 911-7. 33. Webb, D.W., et al., The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol, 1996. 135(1): p. 1-5. 34. Jozwiak, J. and R. Galus, Molecular implications of skin lesions in tuberous sclerosis. Am J Dermatopathol, 2008. 30(3): p. 256-61. 35. Dabora, S.L., et al., Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet, 2001. 68(1): p. 64-80. 36. Aldrich, C.S., et al., Acral lesions in tuberous sclerosis complex: insights into pathogenesis. J Am Acad Dermatol, 2010. 63(2): p. 244-51. 37. Rowley, S.A., F.J. O'Callaghan, and J.P. Osborne, Ophthalmic manifestations of tuberous sclerosis: a population based study. Br J Ophthalmol, 2001. 85(4): p. 420-3. 38. Zimmer-Galler, I.E. and D.M. Robertson, Long-term observation of retinal lesions in tuberous sclerosis. Am J Ophthalmol, 1995. 119(3): p. 318-24. 39. Mennel, S., et al., Current treatment modalities for exudative retinal hamartomas secondary to tuberous sclerosis: review of the literature. Acta Ophthalmol Scand, 2007. 85(2): p. 127-32. 40. Au, K.S., et al., Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med, 2007. 9(2): p. 88-100. 41. Robertson, D.M., Ophthalmic manifestations of tuberous sclerosis. Ann N Y Acad Sci, 1991. 615: p. 17-25. 42. Curatolo, P., R. Bombardieri, and S. Jozwiak, Tuberous sclerosis. Lancet, 2008. 372(9639): p. 657-68. 43. Crino, P.B., K.L. Nathanson, and E.P. Henske, The tuberous sclerosis complex. N Engl J Med, 2006. 355(13): p. 1345-56. 44. Park, S.H., et al., Tuberous sclerosis in a 20-week gestation fetus: immunohistochemical study. Acta Neuropathol, 1997. 94(2): p. 180-6. 45. Levine, D., et al., Tuberous sclerosis in the fetus: second-trimester diagnosis of subependymal tubers with ultrafast MR imaging. AJR Am J Roentgenol, 2000. 175(4): p. 1067-9. 46. Iwasaki, S., et al., MR and CT of tuberous sclerosis: linear abnormalities in the cerebral white matter. AJNR Am J Neuroradiol, 1990. 11(5): p. 1029-34. 47. Goh, S., W. Butler, and E.A. Thiele, Subependymal giant cell tumors in tuberous sclerosis complex. Neurology, 2004. 63(8): p. 1457-61. 48. Baskin, H.J., Jr., The pathogenesis and imaging of the tuberous sclerosis complex. Pediatr Radiol, 2008. 38(9): p. 936-52. 49. Joinson, C., et al., Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med, 2003. 33(2): p. 335-44. 50. Napolioni, V. and P. Curatolo, Genetics and molecular biology of tuberous sclerosis complex. Curr Genomics, 2008. 9(7): p. 475-87. 51. Chu-Shore, C.J., et al., The natural history of epilepsy in tuberous sclerosis complex. Epilepsia, 2010. 51(7): p. 1236-41. 52. Samir, H., H.A. Ghaffar, and M. Nasr, Seizures and intellectual outcome: clinico-radiological study of 30 Egyptian cases of tuberous sclerosis complex. Eur J Paediatr Neurol, 2011. 15(2): p. 131-7. 53. Smalley, S.L., et al., Autism and tuberous sclerosis. J Autism Dev Disord, 1992. 22(3): p. 339-55. 54. Hunt, A., Development, behaviour and seizures in 300 cases of tuberous sclerosis. J Intellect Disabil Res, 1993. 37 ( Pt 1): p. 41-51. 55. Hunt, A. and C. Shepherd, A prevalence study of autism in tuberous sclerosis. J Autism Dev Disord, 1993. 23(2): p. 323-39. 56. Jozwiak, S., et al., Multiple cardiac rhabdomyomas as a sole symptom of tuberous sclerosis complex: case report with molecular confirmation. J Child Neurol, 2005. 20(12): p. 988-9. 57. Jozwiak, S., et al., Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex. Pediatrics, 2006. 118(4): p. e1146-51. 58. Geva, T., et al., Cardiac rhabdomyoma. Rare cause of fetal death. Chest, 1991. 99(1): p. 139-42. 59. Grellner, W. and C. Henssge, Multiple cardiac rhabdomyoma with exclusively histological manifestation. Forensic Sci Int, 1996. 78(1): p. 1-5. 60. Zimmerhackl, L.B., et al., Renal involvement in tuberous sclerosis complex: a retrospective survey. Pediatr Nephrol, 1994. 8(4): p. 451-7. 61. O'Callaghan, F.J., et al., An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int, 2004. 94(6): p. 853-7. 62. Rakowski, S.K., et al., Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int, 2006. 70(10): p. 1777-82. 63. Al-Saleem, T., et al., Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer, 1998. 83(10): p. 2208-16. 64. Casper, K.A., et al., Tuberous sclerosis complex: renal imaging findings. Radiology, 2002. 225(2): p. 451-6. 65. Bakshi, S.S., et al., Aggressive renal angiomyolipoma extending into the renal vein and inferior vena cava - an uncommon entity. Br J Radiol, 2011. 84(1004): p. e166-8. 66. Bissler, J.J., et al., Reduction of postembolization syndrome after ablation of renal angiomyolipoma. Am J Kidney Dis, 2002. 39(5): p. 966-71. 67. Varma, S., et al., Renal epithelioid angiomyolipoma: a malignant disease. J Nephrol, 2011. 24(1): p. 18-22. 68. Lopez-Beltran, A., et al., 2004 WHO classification of the renal tumors of the adults. Eur Urol, 2006. 49(5): p. 798-805. 69. Ewalt, D.H., et al., Renal lesion growth in children with tuberous sclerosis complex. J Urol, 1998. 160(1): p. 141-5. 70. Carsillo, T., A. Astrinidis, and E.P. Henske, Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A, 2000. 97(11): p. 6085-90. 71. Henske, E.P., et al., Frequent progesterone receptor immunoreactivity in tuberous sclerosis-associated renal angiomyolipomas. Mod Pathol, 1998. 11(7): p. 665-8. 72. Logginidou, H., et al., Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Chest, 2000. 117(1): p. 25-30. 73. Brook-Carter, P.T., et al., Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet, 1994. 8(4): p. 328-32. 74. Johnson, S.R., Lymphangioleiomyomatosis. Eur Respir J, 2006. 27(5): p. 1056-65. 75. De Luca, S., C. Terrone, and S.R. Rossetti, Management of renal angiomyolipoma: a report of 53 cases. BJU Int, 1999. 83(3): p. 215-8. 76. Astrinidis, A. and E.P. Henske, Aberrant cellular differentiation and migration in renal and pulmonary tuberous sclerosis complex. J Child Neurol, 2004. 19(9): p. 710-5. 77. Sparling, J.D., et al., Oral findings in 58 adults with tuberous sclerosis complex. J Am Acad Dermatol, 2007. 56(5): p. 786-90. 78. Nakhleh, R.E.M.D., Angiomyolipoma of the Liver. [Review]. 2009: Pathology Case Reviews January/February 2009;14(1):47-49. 79. Kwiatkowski, D.J., V.H. Whittemore, and E.A. Thiele, Tuberous sclerosis complex : genes, clinical features, and therapeutics. 2010, Weinheim: Wiley-Blackwell. 80. Koak, N., et al., Indocyanine green angiography of retinal astrocytomas associated with tuberous sclerosis. Korean J Ophthalmol, 2003. 17(2): p. 145-8. 81. Shields, C.L., et al., Optical coherence tomography of retinal astrocytic hamartoma in 15 cases. Ophthalmology, 2006. 113(9): p. 1553-7. 82. Goodman, M., et al., Cortical tuber count: a biomarker indicating neurologic severity of tuberous sclerosis complex. J Child Neurol, 1997. 12(2): p. 85-90. 83. Lemaitre, L., et al., Imaging of angiomyolipomas. Semin Ultrasound CT MR, 1997. 18(2): p. 100-14. 84. Gomez, M.R., Tuberous Sclerosis Complex. 1999, Cary, NC, USA: Oxford University Press, USA. 85. Prather, P. and P.J. de Vries, Behavioral and cognitive aspects of tuberous sclerosis complex. J Child Neurol, 2004. 19(9): p. 666-74. 86. Krueger, D.A. and H. Northrup, Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol, 2013. 49(4): p. 255-65. 87. Bissler, J.J. and J.C. Kingswood, Renal angiomyolipomata. Kidney Int, 2004. 66(3): p. 924-34. 88. Chu, S.C., et al., Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest, 1999. 115(4): p. 1041-52. 89. Niida, Y., et al., Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis. Hum Mutat, 1999. 14(5): p. 412-22. 90. Jones, A.C., et al., Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet, 1999. 64(5): p. 1305-15. 91. Sancak, O., et al., Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet, 2005. 13(6): p. 731-41. 92. van Slegtenhorst, M., et al., Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science, 1997. 277(5327): p. 805-8. 93. Lamb, R.F., et al., The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol, 2000. 2(5): p. 281-7. 94. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell, 1993. 75(7): p. 1305-15. 95. Maheshwar, M.M., et al., The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis. Hum Mol Genet, 1997. 6(11): p. 1991-6. 96. York, B., et al., Cross-talk between tuberin, calmodulin, and estrogen signaling pathways. Faseb j, 2005. 19(9): p. 1202-4. 97. Janssen, B., et al., Refined localization of TSC1 by combined analysis of 9q34 and 16p13 data in 14 tuberous sclerosis families. Hum Genet, 1994. 94(4): p. 437-40. 98. Povey, S., et al., Two loci for tuberous sclerosis: one on 9q34 and one on 16p13. Ann Hum Genet, 1994. 58(Pt 2): p. 107-27. 99. Dabora, S.L., et al., Characterisation of six large deletions in TSC2 identified using long range PCR suggests diverse mechanisms including Alu mediated recombination. J Med Genet, 2000. 37(11): p. 877-83. 100. Kozlowski, P., et al., Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet, 2007. 121(3-4): p. 389-400. 101. Verhoef, S., et al., Somatic mosaicism and clinical variation in tuberous sclerosis complex. Lancet, 1995. 345(8943): p. 202. 102. Sampson, J.R., et al., Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. Am J Hum Genet, 1997. 61(4): p. 843-51. 103. Huang, J. and B.D. Manning, The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J, 2008. 412(2): p. 179-90. 104. Trindade, A.J., et al., MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM). PLoS One, 2013. 8(3): p. e60014. 105. Romaker, D., et al., MicroRNAs are critical regulators of tuberous sclerosis complex and mTORC1 activity in the size control of the Xenopus kidney. Proc Natl Acad Sci U S A, 2014. 111(17): p. 6335-40. 106. van Bakel, I., et al., Mutations in the TSC2 gene: analysis of the complete coding sequence using the protein truncation test (PTT). Hum Mol Genet, 1997. 6(9): p. 1409-14. 107. Sanger, F. and A.R. Coulson, A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol, 1975. 94(3): p. 441-8. 108. Sanger, F., S. Nicklen, and A.R. Coulson, DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A, 1977. 74(12): p. 5463-7. 109. Bartlett, J.M. and D. Stirling, A short history of the polymerase chain reaction. Methods Mol Biol, 2003. 226: p. 3-6. 110. Rendtorff, N.D., et al., Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations. Hum Mutat, 2005. 26(4): p. 374-83. 111. Schuster, S.C., Next-generation sequencing transforms today's biology. Nat Methods, 2008. 5(1): p. 16-8. 112. Marziali, A. and M. Akeson, New DNA sequencing methods. Annu Rev Biomed Eng, 2001. 3: p. 195-223. 113. Mardis, E.R., The impact of next-generation sequencing technology on genetics. Trends Genet, 2008. 24(3): p. 133-41. 114. Morozova, O. and M.A. Marra, Applications of next-generation sequencing technologies in functional genomics. Genomics, 2008. 92(5): p. 255-64. 115. Mamanova, L., et al., Target-enrichment strategies for next-generation sequencing. Nat Methods, 2010. 7(2): p. 111-8. 116. Lane, V.W. and J.M. Samples, Tuberous sclerosis: case study of early seizure control and subsequent normal development. J Autism Dev Disord, 1984. 14(4): p. 423-7. 117. Vignot, S., et al., mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol, 2005. 16(4): p. 525-37. 118. Gao, X., et al., Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol, 2002. 4(9): p. 699-704. 119. Inoki, K., et al., TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol, 2002. 4(9): p. 648-57. 120. Wheless, J.W. and H. Almoazen, A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex. J Child Neurol, 2013. 28(7): p. 933-6. 121. Nelson, C.P. and M.G. Sanda, Contemporary diagnosis and management of renal angiomyolipoma. J Urol, 2002. 168(4 Pt 1): p. 1315-25. 122. Lawson, K.L. and R.A. Pierson, Maternal decisions regarding prenatal diagnosis: rational choices or sensible decisions? J Obstet Gynaecol Can, 2007. 29(3): p. 240-6. 123. Pergament, E. and D. Pergament, Reproductive decisions after fetal genetic counselling. Best Pract Res Clin Obstet Gynaecol, 2012. 26(5): p. 517-29. 124. Biesecker, B.B., Goals of genetic counseling. Clin Genet, 2001. 60(5): p. 323-30. 125. Veach, P.M., B.S. LeRoy, and D.M. Bartels, Facilitating the genetic counseling process: a practice manual, ed. P.M. Veach. 2003, New York: Springer-Verlag. 126. Hung, C.C., et al., Molecular and clinical analyses of 84 patients with tuberous sclerosis complex. BMC Med Genet, 2006. 7: p. 72. 127. Li, H. and R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics, 2009. 25(14): p. 1754-60. 128. McKenna, A., et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res, 2010. 20(9): p. 1297-303. 129. DePristo, M.A., et al., A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet, 2011. 43(5): p. 491-8. 130. San Lucas, F.A., et al., Integrated annotation and analysis of genetic variants from next-generation sequencing studies with variant tools. Bioinformatics, 2012. 28(3): p. 421-2. 131. Wang, K., M. Li, and H. Hakonarson, ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res, 2010. 38(16): p. e164. 132. Kumar, P., S. Henikoff, and P.C. Ng, Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc, 2009. 4(7): p. 1073-81. 133. Adzhubei, I.A., et al., A method and server for predicting damaging missense mutations. Nat Methods, 2010. 7(4): p. 248-9. 134. Robinson, J.T., et al., Integrative genomics viewer. Nat Biotechnol, 2011. 29(1): p. 24-6. 135. Thorvaldsdottir, H., J.T. Robinson, and J.P. Mesirov, Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform, 2013. 14(2): p. 178-92. 136. Ye, K., et al., Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics, 2009. 25(21): p. 2865-71. 137. Rozen, S. and H. Skaletsky, Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol, 2000. 132: p. 365-86. 138. van den Ouweland, A.M., et al., Characterisation of TSC1 promoter deletions in tuberous sclerosis complex patients. Eur J Hum Genet, 2011. 19(2): p. 157-63. 139. Osborne, J.P., A. Fryer, and D. Webb, Epidemiology of tuberous sclerosis. Ann N Y Acad Sci, 1991. 615: p. 125-7. 140. Curatolo, P., et al., TUBEROUS SCLEROSIS COMPLEX: FROM GENES TO BEHAVIOURAL AND COGNITIVE PHENOTYPES. The International Journal of Child Neuropsychiatry 2005. 2(1): p. 21-26. 141. Tihan, T. and A.M. Adesina, Tuberous Sclerosis Complex. Atlas of Pediatric Brain Tumors, ed. Adekunle M. Adesina, et al. 2010: Springer New York. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56357 | - |
| dc.description.abstract | 結節硬化症(Tuberous Sclerosis Complex)為體染色體顯性遺傳疾病，約有1/3患者是家族性遺傳，而2/3的則是屬於散發型(sporadic)；據研究估計其發生率最高約為1/6,000，男女比例相等。由於TSC1和TSC2基因突變導致患者在身體各部位生成錯構瘤(hamartomas)，使得患者會出現多樣化的症狀，在外表可觀察到臉部皮膚血管纖維瘤或額頭斑塊、指甲(邊)纖維瘤、脫色斑、鯊魚皮斑、牙齦纖維瘤症狀，其餘則是內部器官腫瘤或病變生成，亦合併癲癇、智能不足、自閉症等症狀。
TSC1及TSC2基因的轉譯蛋白分別為Hamartin與Tuberin，此蛋白在mTOR pathway中形成複合物，使Rheb不活化mTORC1，進而阻斷蛋白質轉譯及細胞週期的進行，假若TSC1或TSC2基因發生突變，則Hamartin及Tuberin無法正常結合，導致無法調控細胞增生機制，因此在全身各個器官長腫瘤。 本次研究利用次世代定序做為基因檢測方式，在結節硬化症確診的94個家族中，有78個家族找到基因致病點，16個家族未能找到。而在78個家族中有50個家族屬於點突變、20個家族是小片段缺失或插入，以及8個家族是大片段缺失或重複；在性別比例上患有結節硬化症男性為(42/94)和女性(52/94)，總比例約1：1。 次世代定序的檢測方式，不論是單突變點或小片段缺失或插入皆與Sanger定序結果一致，且較Sanger定序可更敏銳的偵測到鑲嵌體的基因變異點，即便只有6%也可偵測到。大片段缺失或插入在IGV圖上可清楚地看到斷點所在位置。統計利用次世代定序做為大片段插入或缺失檢出率為10%，而TSC1或TSC2基因總檢出率有81%(76/94)。比較次世代定序與傳統的檢測方式，在讀取的序列長度、試劑的用量、所花費的時間及金錢皆優於傳統的檢測方式，因此次世代定序應用於結節硬化症的基因檢測是一項利器。 | zh_TW |
| dc.description.abstract | Tuberous Sclerosis Complex (TSC) is an autosomal dominant genetic disorder. One third of patients are familial cases and two thirds are sporadic cases caused by de novo mutations. The disease is estimated to occur in 1:6000 live births worldwide with nearly equal distribution between females and males. TSC is a genetic multisystem disorder characterized by widespread hamartomas in several organs, including the brain, heart, skin, eyes, kidney, lung, and liver, etc. The clinical manifestations are highly variable, and might include epilepsy, mental retardation, behavioral problems, skin lesions and renal problems, which often cause harm to patients physically and psychologically. The only two known disease-causing genes are TSC1 and TSC2, encoding hamartin and tuberin respectively. The hamartin-tuberin complex inhibits the mammalian target of rapamycin (mTOR) pathway, which controls cell growth, cell proliferation and several other important functions.
In this current study, we applied the next-generation sequencing (NGS) technology for the TSC1 and TSC2 genes. Among the 94 patients with definite TSC diagnosis, we could identify the causative genetic variants for 78 cases. There were 16 cases with no mutation identified. In 78 cases, 50 cases had point mutation, 20 cases had small deletion or insertion (indel) and 8 cases had large deletion or duplication. Our overall detection rate using NGS were 81% (76/94). Among the detected disease-causing variants, large deletion or insertion accounted for approximately 10% (8/76). NGS and Sanger sequencing are equally good at detecting point mutations and small indels. Besides, NGS could be more sensitive to detect mosaic variant. Furthermore, it is possible to clearly detect the breakpoints of large deletion or insertion through Integrative Genomics Viewer (IGV) using NGS reads. In conclusion, NGS can replace traditional genetic testing methods, and serve as cost-effective, sensitive and reliable genetic testing platform for TSC. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T05:24:55Z (GMT). No. of bitstreams: 1 ntu-103-P01448005-1.pdf: 5523002 bytes, checksum: 80c94d6f47ccd3e270d416619e300510 (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | 口試委員會審定書........................................I
中文摘要 ................................................II Abstract................................................III 目 錄 ................................................V 圖目錄..................................................VII 表目錄..................................................VIII 第一章 研究背景與動機.................................. 1 第一節 結節硬化症之疾病介紹............................ 1 第二節 結節硬化症之歷史 ................................2 第三節 結節硬化症之臨床表徵............................4 第一項 皮膚表徵........................................4 第二項 眼晴表徵 ........................................4 第三項 腦部表徵 ........................................5 第四項 心臟表徵 ........................................6 第五項 腎臟表徵 ........................................6 第六項 肺部表徵 ........................................7 第七項 口腔表徵 ........................................7 第八項 其他表徵 ........................................7 第四節 結節硬化症之檢查及診斷..........................8 第一項 結節硬化症之檢查 ................................8 第二項 結節硬化症之診斷 ................................8 第五節 結節硬化症之分子遺傳學研究及基因檢測............11 第一項 分子遺傳學研究..................................11 第二項 基因檢測 ........................................12 第六節 結節硬化症之治療 ................................16 第七節 遺傳諮詢 ........................................17 第八節 研究目的 ........................................18 第二章 研究方法 ........................................19 第一節 檢體來源 ........................................19 第二節 檢體收集 ........................................19 第三節 研究方法與步驟..................................19 第一項 Genomic DNA的萃取與定量分析.....................19 第二項 次世代基因定序分析..............................20 第三項 MLPA分析 ........................................22 第四項 聚合酶連鎖反應(Polymerase Chain Reaction)與Sanger定序分析..................................................23 第四節 遺傳諮詢 ........................................25 第三章 研究結果 ........................................26 第一節 次世代定序結果統計與分析 ........................26 第二節 利用次世代定序找出結節硬化症各種形式基因變異點之例證......................................................28 第一項 錯義突變(Missense mutation).....................28 第二項 無義突變(Nonsense mutation)..................... 30 第三項 移碼突變(Frame-shift mutation)..................31 第四項 鑲嵌體(Mosaicism)............................... 32 第五項 大片段缺失(Large deletion)...................... 36 第六項 大片段的串聯重複(Tandem duplication)............42 第三節 遺傳諮詢結果....................................45 第四章 討論............................................49 第五章 結論............................................51 參考文獻 ................................................52 附錄一..................................................61 | |
| dc.language.iso | zh-TW | |
| dc.subject | Sanger定序 | zh_TW |
| dc.subject | 次世代定序 | zh_TW |
| dc.subject | 基因檢測 | zh_TW |
| dc.subject | 結節硬化症 | zh_TW |
| dc.subject | Tuberous Sclerosis Complex (TSC) | en |
| dc.subject | genetic test | en |
| dc.subject | next generation sequencing (NGS) | en |
| dc.subject | Sanger sequencing | en |
| dc.title | 建立以次世代定序為方法之結節硬化症基因檢測 | zh_TW |
| dc.title | Establishment of next-generation sequencing (NGS)-based genetic testing for tuberous sclerosis complex (TSC) | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 謝豐舟(Fon-Jou Hsieh),楊偉勛(Wei-Shiung Yang) | |
| dc.subject.keyword | 結節硬化症,基因檢測,次世代定序,Sanger定序, | zh_TW |
| dc.subject.keyword | Tuberous Sclerosis Complex (TSC),genetic test,next generation sequencing (NGS),Sanger sequencing, | en |
| dc.relation.page | 64 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2014-08-15 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
| 顯示於系所單位： | 分子醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 未授權公開取用 | 5.39 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。